Neuromed's extended-release hydromorphone successful in US Phase III trials
30 March 2009
John Davis
Please Login to read the full article.
30 March 2009
John Davis
john.davis@informa.com
Neuromed Pharmaceuticals' lead investigational product, the extended-release opioid analgesic Exalgo (hydromorphone HCl), has met its primary efficacy endpoint in its pivotal US Phase III clinical trial, the company reports.
The US rights to the product were acquired from Alza (
Johnson &...
Please Login to read the full article.
RELATED CONTENT
NEWS
- US FDA delay of postsurgery pain drug cuts like a knife for Pacira
- Alkermes' PhII ALKS-5461: new mechanism, opiate receptor modulation, for refractory depression
- US Capitol Capsule: FDA's CDER ends 2011 with 30 new drugs and biologics
- BDSI CEO: Shared fentanyl REMS puts Onsolis on level playing field
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
